Pekin Hardy Strauss’s Teva Pharmaceuticals TEVA Stock Holding History

Pekin Hardy Strauss’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-8,925	Closed	-$411K	–	177
2016 Q3	$411K	Hold	8,925	–	–	0.07%	106
2016 Q2	$448K	Hold	8,925	–	–	0.1%	100
2016 Q1	$478K	Sell	8,925 -4,000	-31%	-$235K	0.11%	98
2015 Q4	$848K	Sell	12,925 -5,695	-31%	-$352K	0.19%	80
2015 Q3	$1.05M	Hold	18,620	–	–	0.24%	70
2015 Q2	$1.1M	Sell	18,620 -353,268	-95%	-$21.8M	0.21%	72
2015 Q1	$23.2M	Sell	371,888 -135,847	-27%	-$7.9M	4.31%	5
2014 Q4	$29.2M	Sell	507,735 -77,888	-13%	-$4.34M	4.29%	2
2014 Q3	$31.5M	Sell	585,623 -134,954	-19%	-$7.15M	5.34%	2
2014 Q2	$37.8M	Sell	720,577 -46,765	-6%	-$2.39M	5.93%	2
2014 Q1	$40.5M	Sell	767,342 -149,700	-16%	-$6.92M	6.6%	2
2013 Q4	$36.8M	Buy	917,042 +168,355	+22%	+$6.63M	5.71%	2
2013 Q3	$28.3M	Buy	748,687 +740,993	+9,631%	+$28.9M	4.48%	5
2013 Q2	$302K	Buy	+7,694	New	+$300K	0.05%	100

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Pekin Hardy Strauss's TEVA Position: Q4 2016 in Review

Pekin Hardy Strauss sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 8,925 shares — an estimated $411K sold.

Pekin Hardy Strauss first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $40.5M in Q1 2014. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Pekin Hardy Strauss reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Pekin Hardy Strauss sold 8,925 Teva Pharmaceuticals shares in Q4 2016, an estimated $411K.
Pekin Hardy Strauss first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Pekin Hardy Strauss's Teva Pharmaceuticals position peaked at $40.5M in Q1 2014.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Pekin Hardy Strauss's 13F filing for Q4 2016, filed 1 Feb 2017.